BioWorld

June 18, 2010

View Archived Issues

OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front

For a firm that has yet to reach Phase II with a lead program, OncoMed Pharmaceuticals Inc. has managed some pretty impressive feats in the past few years. (BioWorld Today) Read More

Neurocrine in $235M Deal with Boehringer for GPR119 Agonists

Read More

Arginetix, Immune Control Merge Two Corridors in Vascular Space

Read More

Aquinox Raises $25M for Blood, Immune Disorders Molecule

Read More

EULAR Roundup

Read More

Stimuvax Hold Lifted in NSCLC; Oncothyreon, EMD Move Ahead

Read More

Stock Movers

Read More

Other News To Note

Read More

Clinic Roundup

Read More